Coronavirus Update - 14th October 2020

Despite the recent rises in Covid-19 cases throughout the UK and Europe, Arcinova remains open for business at full capacity as we have done throughout this pandemic. As the situation continues to evolve, we will keep all our customers and stakeholders informed of our activities through this web-page which is updated on a regular basis.

We would like to take this opportunity to thank our clients and staff for their continued support over this period of restricted movement. 

We fully comply with all government guidance on minimising the risks of COVID-19 and have published our risk assessment here

Our work and case studies

Challenge: A client has developed new product to fulfil an unmet patient need. Pivotal clinical studies require highly sensitive, precise measurement of multiple insulin analogues from a small volume of plasma. Our existing methodologies have enabled successful proof of concept and non-regulated PK studies to be completed, but did not meet the precision necessary for regulatory acceptance. 

Customer:

European Biotech Company 

Outcome:

Following a demonstration in the autumn, a new mass spectrometer was purchased, installed and verified for insulins analysis within four months, in time to meet the client’s timeline for a key clinical trial. Analysis for the trial commenced in the spring, and the system is now analysing samples around the clock. 

Analysis of Insulins Case Study